BioAtla Stock (NASDAQ:BCAB), Quotes and News Summary

Q: What sector and industry does BioAtla (BCAB) operate in?

BioAtla is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

BioAtla Stock (NASDAQ: BCAB) stock price, news, charts, stock research, profile.

Open	$2.420
Close	$2.105
Volume / Avg.	796.590K / 521.055K
Day Range	2.100 - 2.505
52 Wk Range	1.240 - 4.068
Market Cap	$103.408M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	33
Short Interest	12.64%
Days to Cover	8.02

Recent News

Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Avi Kapoor

Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Lisa Levin

Dow Rises Over 100 Points; Rayonier Advanced Materials Shares Plunge

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday. The Dow traded up 0.40% to 33,653.27 while the NASDAQ rose 0.83% to 10,724.37. The S&P 500 also rose, gaining, 0.55% to 3,913.66.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trend

Nov 23

Dec 23

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About BioAtla Inc

Sector

Health Care

Industry

Biotechnology

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy BioAtla (BCAB) stock?

You can purchase shares of BioAtla (NASDAQ: BCAB) through any online brokerage.

View our list of the best stock brokerages.

Who are BioAtla's (BCAB) competitors?

Other companies in BioAtla’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Molecular Partners (NASDAQ:MOLN), Anixa Biosciences (NASDAQ:ANIX), CytomX Therapeutics (NASDAQ:CTMX) and FibroGen (NASDAQ:FGEN).

What is the target price for BioAtla (BCAB) stock?

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JMP Securities on Thursday, March 28, 2024. The analyst firm set a price target for 12.00 expecting BCAB to rise to within 12 months (a possible 458.14% upside). 12 analyst firms have reported ratings in the last year.

Current Stock Price for BioAtla (BCAB)?

The stock price for BioAtla (NASDAQ: BCAB) is $2.15 last updated April 19, 2024 at 6:54 PM EDT.

Does BioAtla (BCAB) pay a dividend?

There are no upcoming dividends for BioAtla.

When is BioAtla (NASDAQ:BCAB) reporting earnings?

BioAtla’s Q1 earnings are confirmed for Thursday, May 9, 2024.

Is BioAtla (BCAB) going to split?

There is no upcoming split for BioAtla.

What sector and industry does BioAtla (BCAB) operate in?

BioAtla is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-